---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-035651"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2025-11-19T23:59:59+00:00"
generated_at: "2026-05-16T18:27:29.808140+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Genprex adds Gabrail Cancer Center as new site for Acclaim-1 and Acclaim-3 Reqorsa trials

## Summary
- Gabrail Cancer Center (Canton, OH) is new clinical trial site for Acclaim-1 (NSCLC) and Acclaim-3 (ES-SCLC) studying Reqorsa gene therapy.
- Acclaim-1 Phase 2 expansion to enroll ~33 patients; interim analysis after 19 patients, enrollment of first 19 expected H1 2026.
- Acclaim-3 Phase 2 expansion to enroll ~50 patients; interim analysis after 25th patient, enrollment of first 25 expected H1 2026.
- Both trials have FDA Fast Track Designation; Acclaim-3 also has Orphan Drug Designation.
- Phase 1 showed no dose-limiting toxicities and early efficacy: some patients had prolonged progression-free survival, one partial response.

## SEC filing metadata
- accession: 0001437749-25-035651
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2025-11-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774925035651/0001437749-25-035651-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774925035651/gnpx20251116c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-035651
- JSON: https://secwatch.observer/filing/0001437749-25-035651.json
- Plain text: https://secwatch.observer/filing/0001437749-25-035651.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.